Lilly’s Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer’s Disease

China is the fourth major market where Kisunla has received approval Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024 INDIANAPOLIS, Dec. 17, 2024 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY)…